These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. How much help does a vaccine-induced T-cell response need? Weber JS; Mulé JJ J Clin Invest; 2001 Mar; 107(5):553-4. PubMed ID: 11238555 [No Abstract] [Full Text] [Related]
3. Cancer immunotherapy: phase II clinical studies with TG4010 (MVA-MUC1-IL2). Acres B J BUON; 2007 Sep; 12 Suppl 1():S71-5. PubMed ID: 17935281 [TBL] [Abstract][Full Text] [Related]
4. DC-based cancer vaccines. Gilboa E J Clin Invest; 2007 May; 117(5):1195-203. PubMed ID: 17476349 [TBL] [Abstract][Full Text] [Related]
5. Active and passive immunotherapy: vaccines and antibodies. Oosterwijk E; Divgi C; Bander NH BJU Int; 2007 May; 99(5 Pt B):1301-4. PubMed ID: 17441928 [No Abstract] [Full Text] [Related]
6. Tumor escape from the immune response: a major hurdle for successful immunotherapy of cancer? Chouaib S Tunis Med; 2005 Dec; 83 Suppl 12():7-10. PubMed ID: 16430055 [No Abstract] [Full Text] [Related]
7. Combining cytokine-induced killer cells with vaccination in cancer immunotherapy: more than one plus one? Thanendrarajan S; Nowak M; Abken H; Schmidt-Wolf IG Leuk Res; 2011 Sep; 35(9):1136-42. PubMed ID: 21652069 [TBL] [Abstract][Full Text] [Related]
8. Immunotherapeutic approaches for renal cancer. Pizza G; de Vinci C; Viza D Folia Biol (Praha); 2002; 48(5):167-81. PubMed ID: 12448765 [No Abstract] [Full Text] [Related]
9. Renal cell carcinoma: recent progress and future directions. Mulders P; Figlin R; deKernion JB; Wiltrout R; Linehan M; Parkinson D; deWolf W; Belldegrun A Cancer Res; 1997 Nov; 57(22):5189-95. PubMed ID: 9371523 [No Abstract] [Full Text] [Related]
10. Adenovirus as vehicle for anticancer genetic immunotherapy. Gallo P; Dharmapuri S; Cipriani B; Monaci P Gene Ther; 2005 Oct; 12 Suppl 1():S84-91. PubMed ID: 16231059 [TBL] [Abstract][Full Text] [Related]
11. Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy. Gridelli C; Rossi A; Maione P; Ferrara ML; Castaldo V; Sacco PC Oncologist; 2009 Sep; 14(9):909-20. PubMed ID: 19726457 [TBL] [Abstract][Full Text] [Related]
12. Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma. Dudek AZ; Mescher MF; Okazaki I; Math VT; Luo X; Curtsinger JM; Miller JS Am J Clin Oncol; 2008 Apr; 31(2):173-81. PubMed ID: 18391603 [TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for glioma: promises and challenges. Han SJ; Zygourakis C; Lim M; Parsa AT Neurosurg Clin N Am; 2012 Jul; 23(3):357-70. PubMed ID: 22748649 [TBL] [Abstract][Full Text] [Related]
14. New approaches to immunoprevention and immunotherapy of neoplasms. Glushkov AN Russ J Immunol; 2002 Oct; 7(3):219-28. PubMed ID: 12674931 [TBL] [Abstract][Full Text] [Related]
15. Cellular vaccine therapies for cancer. Mastrangelo MJ; Sato T; Lattime EC; Maguire HC; Berd D Cancer Treat Res; 1998; 94():35-50. PubMed ID: 9587681 [No Abstract] [Full Text] [Related]
16. Vaccines for colorectal cancer and renal cell carcinoma. Kabaker K; Shell K; Kaufman HL Cancer J; 2011; 17(5):283-93. PubMed ID: 21952277 [TBL] [Abstract][Full Text] [Related]
17. Should dendritic cell-based tumor vaccination be incorporated into standard therapy for newly diagnosed glioblastoma patients? Van Gool S; De Vleeschouwer S Expert Rev Neurother; 2012 Oct; 12(10):1173-6. PubMed ID: 23082731 [No Abstract] [Full Text] [Related]
18. Vaccines to treat cancer--an old approach whose time has arrived. Hellstrom KE; Hellstrom I J Cell Biochem; 2007 Oct; 102(2):291-300. PubMed ID: 17729239 [TBL] [Abstract][Full Text] [Related]